***News Stories Thread*** ONGOING 2019

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
Maggie Nell
Posts: 1134
Joined: Wed May 27, 2015 1:57 am
Location: Melbourne, Australia

Re: ***News Stories Thread*** ONGOING 2019

Postby Maggie Nell » Mon Jul 01, 2019 2:22 am

Society may not want to know about woundedness, or cancer, or mortality, but an increasing number of people are living beyond cancer treatment and being forced to confront precisely these things. Arthur Frank called ours a remission society:” a place where many of us have had cancer and may pass as healthy citizens, but are in fact only on visas.”

We require periodic checkups and know we could be expelled at any time. In such a context, it is even more urgent that those with cancer tell their stories.



“To use a metaphor at a time like this would be obscene”: a study of cancer, poetry and metaphor

This paper will examine the role of metaphor in relation to the scandal of cancer. It will consider the impact of metaphors drawn
from popular culture, biomedicine, alternative medicine, and the holistic health movement.
by Cathy Altmann
University of Melbourne

https://arts.monash.edu/__data/assets/p ... ltmann.pdf
DX April 2015, @ 54
35mm poorly diff. tumour, incidental finding following emergency r. hemicolectomy
for ileo-colic intussusception.
Lymph nodes: 0/22
T3 N0 MX
July 2019 : pending liver U/S, colonoscopy
rut roh

User avatar
CRguy
Posts: 10038
Joined: Sun Feb 10, 2008 6:00 pm

A Chemotherapy-Free Targeted Therapy Defines a New Standard of Care in Metastatic Colorectal Cancer

Postby CRguy » Fri Jul 12, 2019 3:53 pm

The regimen provided the first survival benefit of a chemotherapy-free therapy in prospective, biomarker-defined patients.

https://www.practiceupdate.com/content/ ... 544/55/1/2

Dr. Grothey concluded that triplet therapy using encorafenib + binimetinib + cetuximab and doublet therapy using encorafenib + cetuximab improved overall survival and objective response rates significantly vs the standard of care in patients with BRAFV600E-mutant, metastatic colorectal cancer.
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 10038
Joined: Sun Feb 10, 2008 6:00 pm

Maintenance With Panitumumab Alone vs Panitumumab + Fluorouracil–Leucovorin in Patients With RAS Wild-Type Metastatic Co

Postby CRguy » Fri Jul 12, 2019 3:55 pm

Maintenance With Panitumumab Alone vs Panitumumab + Fluorouracil–Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer

https://www.practiceupdate.com/journals ... rt-insight
TAKE-HOME MESSAGE
• The authors of this prospective, randomized phase II trial compared single-agent anti-EGFR (panitumumab) maintenance therapy with maintenance chemotherapy (fluorouracil and leucovorin) plus panitumumab following induction treatment with panitumumab and FOLFOX-4 in 229 patients with previously untreated RAS wild-type metastatic colorectal cancer. The 10-month progression-free survival was 49.0% with panitumumab and 59.9% with chemotherapy plus panitumumab (P=.01). The combination of fluorouracil, leucovorin, and panitumumab was associated with increased toxicity compared with panitumumab alone.
• Among patients with RAS wild-type metastatic colorectal cancer, progression-free survival was inferior with panitumumab monotherapy compared with panitumumab plus fluorouracil–leucovorin.
– Paul Hampel, MD
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 10038
Joined: Sun Feb 10, 2008 6:00 pm

Prognosis of Microsatellite Instability and/or Mismatch Repair Deficiency Stage III Colon Cancer Patients After Disease

Postby CRguy » Fri Jul 12, 2019 4:02 pm

Prognosis of Microsatellite Instability and/or Mismatch Repair Deficiency Stage III Colon Cancer Patients After Disease Recurrence Following Adjuvant Treatment

https://www.practiceupdate.com/c/86267/ ... rt-insight

TAKE-HOME MESSAGE
• This pooled analysis was designed to evaluate the prognostic significance of microsatellite instability/deficient mismatch repair (MSI/dMMR) status after disease recurrence among patients who received adjuvant treatment for stage III colon cancer. MSI/dMMR tumors were associated with significantly longer survival after recurrence compared with microsatellite stable/proficient MMR (MSS/pMMR) tumors, even in patients treated with only standard oxaliplatin-based adjuvant chemotherapy regimens. The presence of the BRAFV600E mutation was associated with a poor prognosis, irrespective of MSI status.
• The MSI/dMMR phenotype in patients with stage III colon cancer with recurrence was associated with improved survival outcomes compared with the MSS/pMMR phenotype. BRAFV600E mutation was associated with poor outcomes.
– Neil Majithia, MD
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 10038
Joined: Sun Feb 10, 2008 6:00 pm

3 vs 6 Months of Adjuvant FOLFOX or CAPOX for High-Risk Stage II and Stage III Colon Cancer

Postby CRguy » Fri Jul 12, 2019 4:03 pm

3 vs 6 Months of Adjuvant FOLFOX or CAPOX for High-Risk Stage II and Stage III Colon Cancer

https://www.practiceupdate.com/journals ... rt-insight

TAKE-HOME MESSAGE
• This randomized trial was designed to compare 3 versus 6 months of oxaliplatin/ fluoropyrimidine–based adjuvant chemotherapy for high-risk stage II and stage III colon cancer. The overall 3-year disease-free survival (DFS) rate was 77.2% in the 3-month group versus 77.9% in the 6-month group. The 3-year DFS was dependent on the regimen used, consistent with data from the global IDEA project.
• The DFS appears to be associated with the adjuvant regimen chosen, and the regimen and duration should be personalized.
– Neil Majithia, MD
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 10038
Joined: Sun Feb 10, 2008 6:00 pm

Association of Post-Operative Carcinoembryonic Antigen With Survival and Oxaliplatin Benefit in Patients With Stage 2 Co

Postby CRguy » Thu Jul 25, 2019 2:24 pm

TAKE-HOME MESSAGE

This post hoc analysis of a prior clinical trial was designed to evaluate the use of postoperative carcinoembryonic antigen (CEA) levels to determine benefit of adding oxaliplatin to adjuvant therapy for patients with stage II colon cancer.

High postoperative CEA is associated with shorter disease-free survival compared with normal CEA levels. The addition of oxaliplatin to fluoropyrimidine-based therapy was only beneficial among patients with elevated postoperative CEA.

– Neil Majithia, MD

Association of Post-Operative Carcinoembryonic Antigen With Survival and Oxaliplatin Benefit in Patients With Stage 2 Colon Cancer
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 10038
Joined: Sun Feb 10, 2008 6:00 pm

Lateral Nodal Features on Restaging MRI Associated With Lateral Local Recurrence in Low Rectal Cancer

Postby CRguy » Thu Jul 25, 2019 2:29 pm

TAKE-HOME MESSAGE

The authors of this multicenter pooled cohort study of 741 patients with low rectal cancer evaluated the role of restaging MRI in determining which patients may benefit from lateral lymph node dissection after chemoradiotherapy or radiotherapy. There were no lateral local recurrences among patients with shrinkage of lateral nodes from a short-axis size of ≥7 mm on primary MRI to a short-axis node size of ≤4 mm on restaging MRI. Conversely, patients who had persistently enlarged nodes on restaging MRI had a 5-year lateral local recurrence rate of 52.3%.

Restaging MRI has a vital role in informing the need for lateral lymph node dissection, which should always be seriously considered among patients with persistently enlarged nodes in the internal iliac compartment.

– Paul Hampel, MD


Lateral Nodal Features on Restaging MRI Associated With Lateral Local Recurrence in Low Rectal Cancer
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

User avatar
CRguy
Posts: 10038
Joined: Sun Feb 10, 2008 6:00 pm

Proportion of CRC Diagnoses Increased in Adults Younger Than 50

Postby CRguy » Thu Jul 25, 2019 2:35 pm

Abstract

Background
The incidence of colorectal cancer (CRC) in adults younger than 50 years has increased in the United States over the past decades according to Surveillance, Epidemiology, and End Results data. National guidelines conflict over beginning screening at the age of 45 or 50 years.

Methods
This was a retrospective study of National Cancer Data Base data from 2004 to 2015. The Cochran‐Armitage test for trend was used to assess changes in the proportion of cases diagnosed at an age younger than 50 years.

Results
This study identified 130,165 patients diagnosed at an age younger than 50 years and 1,055,598 patients diagnosed at the age of 50 years or older. The proportion of the total number of patients diagnosed with CRC at an age younger than 50 years rose (12.2% in 2015 vs 10.0% in 2004; P < .0001). Younger adults presented with more advanced disease (stage III/IV; 51.6% vs 40.0% of those 50 years old or older). Among men, diagnosis at ages younger than 50 years rose only in non‐Hispanic whites (P < .0001), whereas among women, Hispanic and non‐Hispanic whites had increases in younger diagnoses over time (P < .05). All income quartiles had a proportional increase in younger adults over time (P < .001), with the highest income quartile having the highest proportion of younger cases. The proportion of younger onset CRC cases rose in urban areas (P < .001) but did not rise in rural areas.

Conclusions
The proportion of persons diagnosed with CRC at an age younger than 50 years in the United States has continued to increase over the past decade, and younger adults present with more advanced disease. These data should be considered in the ongoing discussion of screening guidelines.

Proportion of CRC Diagnoses Increased in Adults Younger Than 50
Caregiver x 4
Stage IV A rectal cancer/lung met
12 Year survivor
my life is an ongoing totally randomized UNcontrolled experiment with N=1 !
Review of my Journey so far

Beckster
Posts: 399
Joined: Thu Jan 12, 2017 3:01 pm
Location: New Jersey

Maintenance Panitumumab Monotherapy Tested Against Combination with Fluorouracil-Leucovorin for Colorectal Cancer

Postby Beckster » Fri Jul 26, 2019 6:31 pm

Maintenance therapy with single-agent anti-EGFR panitumumab resulted in inferior outcomes compared with panitumumab combined with fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer, according to the results of the phase II VALENTINO study.


https://www.cancernetwork.com/colorecta ... colorectal
57/F
DX:(CC) 10/19/16
11/4/16- Lap right hemi(cecum)
CEA- Pre Op (1.9), Pre Chemo (2.5)
Type: Adenocarcinoma
Tumor size:3.5 cm x 2.5 x 0.7 cm
Grade: G3 (path) G2 (pre-op)
TNM: T3N0M0/IIA
LN: 0/24
LVI present
Surgical margins: clear
MSS
12/27/2016 - Capeox, anaphylactic reaction
1/2/17 to 6/9/17- Xeloda monotherapy
6/17,12/17,6/18,12/18 6/19 CT Scan NED :D
CEA- 6/17- 3.6, 9/17- 2.8 12/17-2.8, 3/18-3.1, 6/18-3.0, 9/18 2.8, 12/18 2.5 3/19 3.1 6/19 3.1 9/19 2.6 12/19 2.8
Clear Colonoscopy 10/17, 11/19 :D

Jannine
Posts: 185
Joined: Wed Jun 20, 2018 7:46 am
Location: Maryland, USA

Sugary drink consumption and risk of cancer

Postby Jannine » Tue Aug 06, 2019 3:55 pm

From BMJ 2019; 366 (Published 10 July 2019)

Conclusions:
In this large prospective study, the consumption of sugary drinks was positively associated with the risk of overall cancer and breast cancer. 100% fruit juices were also positively associated with the risk of overall cancer. These results need replication in other large scale prospective studies. They suggest that sugary drinks, which are widely consumed in Western countries, might represent a modifiable risk factor for cancer prevention.

https://www.bmj.com/content/366/bmj.l2408
DX: sigmoid colon cancer 5/2018. 48 F
laparoscopic sigmoid resection (24 cm removed); no stoma.
7.5cm adenocarcinoma -- mod. diff.
1 noncontiguous tumor deposit removed; 0/31 lymph nodes
T3 pN1c M0
5/18 before surgery, CEA 11.2
6/18 began FOLFOX
7/18: CEA 1.9; added neulasta post infusion
9/18: CEA 2.8
10/18: 25% chemo reduction
11/18: CEA 1.8
7/19 CT scan clear

User avatar
Jacques
Posts: 566
Joined: Sun Dec 28, 2014 10:38 am
Location: Occitanie

ERAS: Enhanced Recovery after Surgery

Postby Jacques » Thu Aug 15, 2019 12:12 am

ERAS: Enhanced Recovery after Surgery
https://amp.greenvilleonline.com/amp/1879185001
    ERAS includes
    ● More education for patients about what they're going to experience

    ● Better control of chronic medical conditions like diabetes prior to surgery

    ● Reducing anxiety

    ● Ways to control pain other than opioids

    ● Getting up and eating as soon as possible after surgery
ERAS Handbook
http://paagreenville.com/assets/docs/ERAS_Handbook.pdf

Clinical Practice Guidelines for Enhanced Recovery
https://www.fascrs.org/sites/default/files/downloads/publication/clinical_practice_guidelines_for_enhanced_recovery.3.pdf

Wewillfight
Posts: 18
Joined: Sun Mar 03, 2019 5:27 am

Re: ***News Stories Thread*** ONGOING 2019

Postby Wewillfight » Mon Aug 26, 2019 4:42 pm

https://www.zucero.com.au/news-articles ... wel-cancer

Zucero Therapeutics to investigate pixatimod in combination with Opdivo in bowel cancer
Zucero is pleased to announce that an amendment to an ongoing study entitled “An open-label, multi-centre Phase Ib study of the safety and tolerability of IV infused PG545 in combination with nivolumab in patients with advanced solid tumours with an expansion cohort in patients with metastatic pancreatic cancer” has been approved by the lead Human Research Ethics Committee (HREC), expanding the study to include patients with a particular form of bowel cancer known as microsatellite stable metastatic colorectal cancer (MSS mCRC).
40 y/o
Diag Nov 2016 stage IIIc, surgery, colostomy, 2 lymph involved
6 months FOLFOX
NED
Nov 2018 recurrence , surgery , some spread to pertineum
Jan-June 2019 Folfiri+Cetux
Clear scans
August 2019: small bowel inflammation, partial blockage symptoms

User avatar
Jacques
Posts: 566
Joined: Sun Dec 28, 2014 10:38 am
Location: Occitanie

Global patterns and trends in colorectal cancer incidence in young adults

Postby Jacques » Fri Nov 01, 2019 11:40 am

Global patterns and trends in colorectal cancer incidence in young adults
http://dx.doi.org/10.1136/gutjnl-2019-319511
CRC incidence increased exclusively in young adults in nine high-income countries spanning three continents, potentially signalling changes in early-life exposures that influence large bowel carcinogenesis.

Beckster
Posts: 399
Joined: Thu Jan 12, 2017 3:01 pm
Location: New Jersey

Shorter Adjuvant Oxaliplatin-Based Therapy Less Effective in High-Risk Stage II CRC

Postby Beckster » Tue Nov 05, 2019 10:35 am

57/F
DX:(CC) 10/19/16
11/4/16- Lap right hemi(cecum)
CEA- Pre Op (1.9), Pre Chemo (2.5)
Type: Adenocarcinoma
Tumor size:3.5 cm x 2.5 x 0.7 cm
Grade: G3 (path) G2 (pre-op)
TNM: T3N0M0/IIA
LN: 0/24
LVI present
Surgical margins: clear
MSS
12/27/2016 - Capeox, anaphylactic reaction
1/2/17 to 6/9/17- Xeloda monotherapy
6/17,12/17,6/18,12/18 6/19 CT Scan NED :D
CEA- 6/17- 3.6, 9/17- 2.8 12/17-2.8, 3/18-3.1, 6/18-3.0, 9/18 2.8, 12/18 2.5 3/19 3.1 6/19 3.1 9/19 2.6 12/19 2.8
Clear Colonoscopy 10/17, 11/19 :D

Beckster
Posts: 399
Joined: Thu Jan 12, 2017 3:01 pm
Location: New Jersey

Circulating Tumor DNA Analysis May Indicate Adjuvant Therapy Efficacy for Stage III CRC

Postby Beckster » Tue Nov 19, 2019 4:26 pm

The University of Pittsburgh in collaboration with the National Cancer Institute is also currently recruiting for a clinical trial evaluating ctDNA as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer.


https://www.cancernetwork.com/colorecta ... 67F54E7A36
57/F
DX:(CC) 10/19/16
11/4/16- Lap right hemi(cecum)
CEA- Pre Op (1.9), Pre Chemo (2.5)
Type: Adenocarcinoma
Tumor size:3.5 cm x 2.5 x 0.7 cm
Grade: G3 (path) G2 (pre-op)
TNM: T3N0M0/IIA
LN: 0/24
LVI present
Surgical margins: clear
MSS
12/27/2016 - Capeox, anaphylactic reaction
1/2/17 to 6/9/17- Xeloda monotherapy
6/17,12/17,6/18,12/18 6/19 CT Scan NED :D
CEA- 6/17- 3.6, 9/17- 2.8 12/17-2.8, 3/18-3.1, 6/18-3.0, 9/18 2.8, 12/18 2.5 3/19 3.1 6/19 3.1 9/19 2.6 12/19 2.8
Clear Colonoscopy 10/17, 11/19 :D


Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: No registered users and 25 guests